Activity of Retapamulin (SB-275833), a Novel Pleuromutilin, against Selected Resistant Gram-Positive Cocci-Reference-Cited by-同舟云学术

Activity of Retapamulin (SB-275833), a Novel Pleuromutilin, against Selected Resistant Gram-Positive Cocci

Published:2006-07 Issue:7 Volume:50 Page:2583-2586
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Jones Ronald N.¹²,Fritsche Thomas R.¹,Sader Helio S.¹,Ross James E.¹

Affiliation:

1. JMI Laboratories, North Liberty, Iowa 52317

2. Tufts University School of Medicine, Boston, Massachusetts 02111

Abstract

ABSTRACT Retapamulin (SB-275833), the first pleuromutilin to be developed for human topical use, was tested against a selected population of staphylococci and β-hemolytic streptococci. The MIC 90 results for retapamulin were 0.12 μg/ml for Staphylococcus aureus and ≤0.03 μg/ml for Streptococcus pyogenes ; no cross-resistance was observed for organism subsets resistant to oxacillin, erythromycin, or mupirocin.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01432-05

Reference14 articles.

1. Brooks, G., W. Burgess, D. Colthurst, J. D. Hinks, E. Hunt, M. J. Pearson, B. Shea, A. K. Takle, J. M. Wilson, and G. Woodnutt. 2001. Pleuromutilins. 1. The identification of novel mutilin 14-carbamates. Bioorg. Med. Chem.9:1221-1231.

2. Clinical and Laboratory Standards Institute. 2005. Performance standard for antimicrobial susceptibility testing. Document M100-S15. CLSI Wayne Pa.

3. Deshpande, L. M., A. M. Fix, M. A. Pfaller, The SENTRY Antimicrobial Surveillance Program Participants Group, and R. N. Jones. 2002. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program 2000: correlations of results from disk diffusion, Etest and reference dilution methods. Diagn. Microbiol. Infect. Dis.42:283-290.

4. Fritsche, T. R., H. S. Sader, M. G. Stilwell, M. J. Dowzicky, and R. N. Jones. 2005. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn. Microbiol. Infect. Dis.52:195-201.

5. Hunt, E. 2000. Pleuromutilin antibiotics. Drugs Future25:1163-1168.

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel pleuromutilin derivatives conjugated with phenyl-sulfide and boron-containing moieties as potent antibacterial agents against antibiotic-resistant bacteria;European Journal of Medicinal Chemistry;2024-11

2. Synthesis of retapamulin from plueromutilin enhancing the purity and yield via altered halogenations process;Journal of the Indian Chemical Society;2024-08

3. Rh(III)-Catalyzed Diastereo- and Enantioselective Regiodivergent (Hetero)Arylamidation of (Homo)Allylic Sulfides;Journal of the American Chemical Society;2024-03-28

4. Antimicrobial resistance characteristics and phylogenetic relationships of pleuromutilin-resistant Enterococcus isolates from different environmental samples along a laying hen production chain;Journal of Environmental Sciences;2024-03

5. Antistaphylococcal discovery pipeline; where are we now?;European Journal of Medicinal Chemistry;2024-02